Advertisement

The Discovery of MAP30 and Elucidation of its Medicinal Activities

  • Sylvia Lee-Huang
  • Philip Lin Huang
  • Paul Lee Huang
Chapter

Abstract

In this chapter, we review the discovery of MAP30, a novel multifunctional antiviral and anti-tumor plant protein, and elucidation of its medicinal properties. MAP30, M omordica A ntiviral P rotein 30 kD, is isolated from the medicinal plant Momordica charantia. Biochemical and biophysical studies have yielded important insights into the structure, function and mechanism of MAP30. Column chromatography by ionic exchange, affinity binding and size fractionation were applied for the isolation and purification of MAP30. Protein and nucleotide sequencing were used to elucidate the structure of this protein and its gene. The gene encoding MAP30 was cloned and expressed by recombinant technology. Structure activity mapping was performed using 3D-structure determination, bioinformatics and molecular modeling, together with bioactivity confirmation. Results from these studies demonstrate how cutting-edge modern approaches can be applied to discover medicinal activities from natural products and to define their molecular structure, biological function, and mechanisms of action.

Keywords

Bitter Melon Herpes Simplex Virus Medicinal Activity World Health Organization Study Uninfected Target Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Work done in this review was supported in part by NIH grants R01 AI31343, R01 AT01383, and by Blackout Funding. The authors are grateful to Helen C. Lin for her support and encouragement.

References

  1. 1.
    Robinson MM, Zhang X (2011) Traditional medicines, issues and challenges. WHO, GenevaGoogle Scholar
  2. 2.
    Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey SA, Van Rompay M, Kessler RC (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280:1569–1575PubMedCrossRefGoogle Scholar
  3. 3.
    Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL (1993) Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 328(4):246–252PubMedCrossRefGoogle Scholar
  4. 4.
    Wolsko PM, Eisenberg DM, Davis RB, Ettner SL, Phillips RS (2002) Insurance coverage, medical conditions, and visits to alternative medicine providers: results of a national survey. Arch Intern Med 162(3):281–287PubMedCrossRefGoogle Scholar
  5. 5.
    Eisenberg DM, Kessler RC, Van Rompay MI, Kaptchuk TJ, Wilkey SA, Appel S, Davis RB (2001) Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med 135(5):344–351PubMedGoogle Scholar
  6. 6.
    Kessler RC, Davis RB, Foster DF, Van Rompay MI, Walters EE, Wilkey SA, Kaptchuk TJ, Eisenberg DM (2001) Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 135(4):262–268PubMedGoogle Scholar
  7. 7.
    Nahin RL, Barnes PM, Stussman BJ, Bloom B (2009) Cost of CAM and frequency of visits to CAM prectitioners: United States, 2007 National health statistics reports; no 18. National Center for Health Statistics, HyattsvilleGoogle Scholar
  8. 8.
    Lee-Huang S, Huang PL, Zhang D, Lee JW, Bao J, Sun YT, Chang Y-T, Zhang J, Huang PL (2007) Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol: Part I. Fusion inhibition. Biochem Biophys Res Commun 354:872–878PubMedCrossRefGoogle Scholar
  9. 9.
    Lee-Huang S, Huang PL, Zhang D, Lee JW, Bao J, Sun YT, Chang Y-T, Zhang J, Huang PL (2007) Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol: Part II. Integrase inhibition. Biochem Biophys Res Commun 354:879–884PubMedCrossRefGoogle Scholar
  10. 10.
    Bao J, Zhang DW, Zhang JZH, Huang PL, Huang PL, Lee-Huang S (2007) Computational study of bindings of olive leaf extract (OLE) to HIV-1 fusion protein gp41. FEBS Lett 581:2737–2742PubMedCrossRefGoogle Scholar
  11. 11.
    Lee-Huang S, Zhang L, Huang PL, Chang YT, Huang PL (2003) Anti-HIV activity of olive leaf extract (OLE) and modulation of host cell gene expression by HIV-1 infection and OLE treatment. Biochem Biophys Res Commun 307:1029–1037PubMedCrossRefGoogle Scholar
  12. 12.
    Lee-Huang S, Maiorov V, Huang PL, Lee HC, Ng A, Chang Y-T, Kallenbach N, Huang PL, Chen HC (2005) Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity. Biochemistry 44:4648–4655PubMedCrossRefGoogle Scholar
  13. 13.
    Lee-Huang S, Huang PL, Huang PL, Sun YT, Kung HF, Blithe DL, Chen HC (1999) Lysozyme and ribonucleases as anti-HIV components in beta-core preparations of hCG. Proc Natl Acad Sci U S A 96:2678–2681PubMedCrossRefGoogle Scholar
  14. 14.
    Bourinbaiar AS, Lee-Huang S (1995) Anti-HIV effect of beta subunit of human chorionic gonadotropin (βhCG) in vitro. Immunol Let 44:13–18CrossRefGoogle Scholar
  15. 15.
    Lee-Huang S, Huang PL, Nara PL, Chen HC, Kung HF, Huang P, Huang HI, Huang PL (1990) MAP 30: a new inhibitor of HIV-1 infection and replication. FEBS Letts 272:12–18CrossRefGoogle Scholar
  16. 16.
    Lee-Huang S, Huang PL, Kung HF, Li BQ, Huang PL, Huang P, Huang HI, Huang PL, Chen HC (1991) TAP 29: an anti-human immunodeficiency virus protein from Trichosanthes kirilowii that is nontoxic to intact cells. Proc Natl Acad Sci U S A 88:6570–6574PubMedCrossRefGoogle Scholar
  17. 17.
    Lee-Huang S, Kung HF, Huang PL, Huang PL, Li B-Q, Huang P, Huang HI, Chen HC, Huang PL (1991) A new class of anti-HIV agents: GAP 31, DAP 30 and DAP 32. FEBS Letts 291:139–144CrossRefGoogle Scholar
  18. 18.
    Huang PL, Sun YT, Chen HC, Huang PL, Lee-Huang S (1999) Proteolytic fragments of anti-HIV and anti-tumor proteins MAP30 and GAP31 are biologically active. Biochem Biophys Res Commun 262:615–623PubMedCrossRefGoogle Scholar
  19. 19.
    Lee-Huang S, Huang PL, Chen HC, Huang PL, Bourinbaiar AS, Huang HI, Kung HF (1995) Anti-HIV and anti-tumor activities of recombinant MAP 30 of bitter melon. Gene 161:151–156PubMedCrossRefGoogle Scholar
  20. 20.
    Arazi T, Huang PL, Huang PL, Zhang L, Shiboleth YM, Gal-On A, Lee-Huang S (2002) Production of antiviral and antitumor proteins MAP30 and GAP31 in cucurbits using the plant virus vector ZYMV–AGII. Biochem Biophys Res Commun 292:441–448PubMedCrossRefGoogle Scholar
  21. 21.
    Rybak SM, Lin JJ, Newton DL, Kung HF, Monks A, Chen HC, Huang PL, Huang PL, Lee-Huang S (1994) In vitro anti-tumor activity of the plant ribosome inactivating proteins MAP 30 and GAP 31. Int J Onc 5:1171–1176Google Scholar
  22. 22.
    Lee-Huang S, Huang PL, Sun YT, Kung HF, Huang PL, Murphy WJ (2000) Inhibition of human breast tumor MDA-MB-231 xenografts and HER2 expression in SCID mice by anti-tumor agents GAP31 and MAP30. Anticancer Res 20:653–659Google Scholar
  23. 23.
    Lee-Huang S, Huang PL, Chen HC, Kung HF, Nara PL, Li BQ, Huang PL, Huang HI, Huang PL (1992) Plant proteins with antiviral activity against HIV. In: Chu CK, Cutler HG (eds) Natural products as antiviral agents. Plenum, New York, pp 153–170CrossRefGoogle Scholar
  24. 24.
    Schreiber CA, Sun YT, Wan L, Krey LC, Lee-Huang S (1999) Anti-HIV agents, MAP30 and GAP31 are not toxic to human spermatocytes: potential use of these agents against sexual transmission of HIV-1. Steril Ferti 72:686–690CrossRefGoogle Scholar
  25. 25.
    Lee-Huang S, Huang PL, Kong XP, Schapira M, Huang PL (2003) Novel anti-HIV and anti-tumor proteins MAP30 and GAP31: molecular, biochemical and structural insights into biological activities and mechanism. Recent Res Devel Biophys Biochem 81:235–257Google Scholar
  26. 26.
    Bourinbaiar AS, Lee-Huang S (1995) Potentiation of anti-HIV activity of anti-inflammatory drugs dexamethasone and indomethacin, by MAP 30, the antiviral agent from bitter melon. Biochem Biophys Res Commun 208:779–785PubMedCrossRefGoogle Scholar
  27. 27.
    Bourinbaiar AS, Lee-Huang S (1996) The activity of plant-derived antiretroviral proteins MAP30 and GAP31 against herpes simplex virus infection in vitro. Biochem Biophys Res Commun 219:923–929PubMedCrossRefGoogle Scholar
  28. 28.
    Sun YT, Huang PL, Li JJ, Huang YQ, Zhang L, Huang PL, Lee-Huang S (2001) Anti-HIV agent MAP30 modulates the expression profile of viral and cellular genes for proliferation and apoptosis in AIDS-related lymphoma cells infected with kaposi’s sarcoma-associated virus. Biochem Biophys Res Commun 287:983–994PubMedCrossRefGoogle Scholar
  29. 29.
    Huang PL, Chen HC, Kung HF, Huang PL, Huang P, Huang HI, Lee–Huang S (1992) Anti-HIV plant proteins catalyze topological changes of DNA into inactive forms. BioFactors 4:37–41PubMedGoogle Scholar
  30. 30.
    Lee-Huang S, Kung HF, Huang PL, Bourinbaiar AS, Morell JL, Brown JH, Huang PL, Tsai WP, Chen AY, Huang HI, Chen HC (1994) HIV-1 inhibition, DNA binding, RNA binding and ribosome inactivation activities in the N-terminal segments of the plant anti-HIV protein GAP 31. Proc Natl Acad Sci U S A 91:12208–12212PubMedCrossRefGoogle Scholar
  31. 31.
    Lee-Huang S, Huang PL, Huang PL, Bourinbaiar AS, Chen HC, Kung HF (1995) Inhibition of HIV-1 integrase by plant antiviral proteins MAP 30 and GAP 31. Proc Natl Acad Sci U S A 92:8818–8822PubMedCrossRefGoogle Scholar
  32. 32.
    Lee-Huang S, Kung HF, Chen HC, Huang PL, Rybak SM, Huang PL, Bourinbaiar AS, Musayev F, Liaw YC (1994) Crystallization and preliminary X-ray analysis of GAP 31: an anti-HIV protein. J Mol Biol 240:92–94PubMedCrossRefGoogle Scholar
  33. 33.
    Wang YX, Nouri N, Jacob J, Palmer I, Stahl SJ, Kaufman JD, Huang PL, Huang PL, Heather E, Pommier Y, Wingfield PT, Lee-Huang S, Bax A, Torchia DA (1999) Solution structure of anti-HIV and anti-tumor protein MAP30: structural insights into its multiple functions. Cell 99:433–442PubMedCrossRefGoogle Scholar
  34. 34.
    Wang YX, Jacob J, Wingfield PT, Palmer I, Stahl SJ, Kaufman JD, Huang PL, Huang PL, Lee-Huang S, Torchia DA (2000) Anti-HIV and anti-tumor protein MAP30, a 30 kDa single strand type-1 RIP, shares similar secondary structure and β-sheet topology with the A chain of ricin, a type-II RIP. Prot Sci 9:138–144CrossRefGoogle Scholar
  35. 35.
    Wang XY, Marquardt J, Wingfield P, Stahl SJ, Lee-Huang S, Torchia D, Bax A (1999) Simultaneous measurement of 1H–15N, 1H–13C′ and 15N–13C′ dipole coupling in a perdeuterated 30 kDa protein dissolved in a dilute liquid crystalline phase. J Am Chem Soc 120:7385–7386CrossRefGoogle Scholar
  36. 36.
    Wang XY, Jacob J, Cordier F, Wingfield P, Stahl SJ, Lee-Huang S, Torchia D, Grzesiek S, Bax A (1999) Measurement of (3 h)J(NC′) connectivities across hydrogen bonds in a 30 kDa protein. J Biomol NMR 14:181–184PubMedCrossRefGoogle Scholar
  37. 37.
    Huang PL, Huang PL, Lee-Huang S (2010) Oleuropein and related compounds reduce atherosclerosis. Open Conf Proc J 1:81–86Google Scholar
  38. 38.
    Lee-Huang S, Huang PL, Zhang D, Zhang JZH, Huang PL (2012) Oleuropein and related compounds from olive plants modulate adipogenesis. Open Conf Proc J (in press) Google Scholar
  39. 39.
    Hartono YD, Lee AN, Lee-Huang S, Zhang D (2011) Computational study of bindings of HL9, a nonapeptide fragment of human lysozyme, to HIV-1 fusion protein gp41. Bioorg Med Chem Lett 21:1607–1611PubMedCrossRefGoogle Scholar
  40. 40.
    Lee-Huang S, Huang PL, Huang PL (2011) Live-cell real-time imaging reveals role of mitochondria in cell-to-cell transmission of HIV-1. Biochem Biophys Res Commun 415(2):384–389PubMedCrossRefGoogle Scholar
  41. 41.
    Fang EF, Zhang CZ, Wong JH, Shen JY, Li CH, Ng TB (2012) The MAP30 protein from bitter gourd (Momordica charantia) seeds promotes apoptosis in liver cancer cells in vitro and in vivo. Cancer Lett 324(1):66–74 (Epub 9 May 2012)Google Scholar
  42. 42.
    Meng Y, Liu S, Li J, Meng Y, Zhao X (2012) Preparation of an antitumor and antivirus agent: chemical modification of α-MMC and MAP30 from Momordica charantia L. with covalent conjugation of polyethyelene glycol. Int J Nanomed 7:3133–3142 (Epub 27 June 2012)Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Sylvia Lee-Huang
    • 1
  • Philip Lin Huang
    • 2
  • Paul Lee Huang
    • 3
  1. 1.Department of Biochemistry and Molecular PharmacologyNew York University School of MedicineNew YorkUSA
  2. 2.American BioScienceBostonUSA
  3. 3.Department of MedicineHarvard Medical School and Massachusetts General HospitalBostonUSA

Personalised recommendations